Drug Trial Radar · NCT06945406
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
May 16, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Apr 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.
Conditions
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
Interventions
LY4057996 SCDrug
Administered SC
LY4057996 IVDrug
Administered IV
Placebo SCDrug
Administered SC
Placebo IVDrug
Administered IV
Degludec SCDrug
Administered SC
Lispro SCDrug
Administered SC
Degludec IVDrug
Administered IV
Pre-study basal insulin SCDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline to Study Completion (Up to 47 Weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institut für Stoffwechselforschung
Neuss, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.